Remembering the Lessons of HIV/AIDS

Ronald Valdiserri

As some readers of this blog may already know, at the end of next month I will retire from the federal government after 27 years of service. I don’t plan to leave the field of public health; I’m just changing it up with a move to join the faculty of Johns Hopkins Bloomberg School of…

FDA Issues Final Industry Guidance for Developing Antiretroviral Drugs for HIV Treatment


This week, FDA announced the availability of a final guidance [PDF 610 KB] for industry entitled “Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment.” The guidance provides recommendations for the development of antiretroviral drugs regulated within the FDA Center for Drug Evaluation and Research for the treatment of HIV infection. This guidance assists sponsors in…

FDA approves new treatment for HIV


The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The CDC estimates that 1.2 million persons ages 13 years and older are living…

Every Dose, Every Day (TM): New Tool to Improve Medication Adherence

Every Dose Every Day image

Editor’s Note: The Centers for Disease Control has developed a new digital toolkit to promote medical adherence. This online resource includes a mobile app and can be used by providers as well as people living with HIV. CDC recently published the Every Dose, Every DayTM toolkit online. This toolkit offers assistance to both health care…

CDC Supports New WHO Early Release HIV Treatment and PrEP Guidelines

CDC Logo

For Immediate Release: Wednesday, September 30, 2015 Contact: Media Relations, Office of Communication (404) 639-3286 CDC welcomes today’s announcement by the World Health Organization (WHO) of new Early Release HIV Treatment and Pre-Exposure Prophylaxis (PrEP) guidelines that will significantly increase the number of people eligible for life-saving anti-retroviral treatment (ART) and expand access to a powerful…

Articles Highlight Ryan White HIV/AIDS Program Role Providing HIV Care and Treatment Services

ryan white 25 years rectangle

As the Ryan White HIV/AIDS Program (RWHAP) commemorates its 25th this summer, two new articles published this week highlight the critical role the Program has in providing care and treatment services to low income people living with HIV in the United States. According to a new article in the Journal of the American Medical Association,…

A Conversation with Dr. Anthony Fauci: Results from the START Trial and Implications for the Global Treatment of HIV

Anthony Fauci

Last week, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) released the exciting results of the Strategic Timing of Antiretroviral Treatment (START) study, a randomized, controlled clinical trial to more clearly define the optimal time and benefits for people with HIV to begin antiretroviral therapy (ART). Given the implications of the study, sat…

Starting antiretroviral treatment early improves outcomes for HIV-infected individuals

nih logo

For Immediate Release: Wednesday, May 27, 2015 NIH-funded trial results likely will impact global treatment guidelines A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune…